# MOTS-c: Research Overview — Chai Peptides > A literature summary of MOTS-c, a mitochondrial-derived peptide studied for AMPK activation and metabolic-signaling research. Covers mechanism, cited findings, evidence gaps, and regulatory status. No human dosing, no medical advice. A 16-amino-acid peptide encoded inside mitochondrial DNA, studied for its role in cellular energy sensing — with a research base built entirely on cells, mice, and human biomarker associations. ## The short version MOTS-c is one of a small class of *mitochondrial-derived peptides* — short protein fragments encoded not in the cell's main nuclear genome but inside the DNA of mitochondria, the organelles that generate cellular energy. Specifically, MOTS-c comes from a short reading frame inside the *12S ribosomal RNA* gene (MT-RNR1). Researchers are interested in it because it appears to activate AMPK, a master switch cells use to sense and manage their fuel supply, and because a 2024 study identified a specific molecular target — an enzyme called casein kinase 2 (CK2) — that MOTS-c directly binds and activates [1]. What MOTS-c is *not*, at least not yet, is a studied human therapy. No completed human clinical trial has tested exogenous MOTS-c for any outcome. Everything below is drawn from cell experiments, mouse and rat studies, and a small number of human observational studies that measure naturally circulating MOTS-c rather than administering it. This page describes that evidence exactly as it stands — it does not recommend a dose or a use for any person. ## What it is MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1) — part of the mitochondrial genome itself rather than the much larger nuclear genome most genes come from. The sequence is highly conserved across mammalian species, which researchers take as a signal that it does something biologically important, though exactly what is still being worked out. Because it is mitochondrial-encoded, MOTS-c is grouped with a handful of other 'mitochondrial-derived peptides' (MDPs) discovered over the past two decades — humanin was the first, MOTS-c among the better-studied since. It circulates in blood and can be detected and quantified in human serum, which is how the observational studies described below were conducted; but administering synthetic MOTS-c to humans as an intervention has not been tested in a published clinical trial. ## How it works MOTS-c's best-characterized action is inhibition of the folate cycle and de novo purine biosynthesis, which raises a metabolite called AICAR and, through that route, activates AMP-activated protein kinase (AMPK) — the same fuel-sensing pathway targeted by metformin and by exercise itself. AMPK activation shifts cells toward using stored fuel and improving insulin sensitivity, primarily demonstrated in skeletal muscle. Under metabolic stress, MOTS-c also translocates from the mitochondrion into the cell nucleus, where it appears to help regulate nuclear gene expression in an AMPK-dependent way — including genes controlled by NRF2, a transcription factor central to the cell's antioxidant stress response. This was the first demonstrated instance of 'retrograde' signaling by a mitochondrial-encoded peptide — the mitochondrion talking back to the nucleus rather than the reverse [5]. A 2024 study went further, identifying casein kinase 2 (CK2) as a direct binding partner: MOTS-c activates CK2 in muscle tissue (improving glucose uptake and preventing atrophy) while suppressing it in fat tissue — a tissue-specific effect researchers propose underlies its broader metabolic profile [1]. ## What the research shows *Direct molecular target (2024).* Working in mice — young, aged, high-fat-diet-fed, and immobilized — plus cell-free biochemical assays, researchers showed that MOTS-c directly binds and activates casein kinase 2 (CK2), with tissue-specific effects: CK2 activation in muscle and suppression in fat. The study demonstrated prevention of skeletal-muscle atrophy and enhanced muscle glucose uptake through this mechanism [1]. *Human cardiovascular-risk association (2024).* In a prospective multicenter cohort of 94 chronic hemodialysis patients followed for a median of 26.5 months, circulating MOTS-c levels were independently associated with a composite of all-cause mortality and non-fatal cardiovascular events, and adding MOTS-c to a risk model improved its discriminative accuracy (ROC AUC rising from 0.727 to 0.743) [2]. This is among the strongest human clinical-association data available for MOTS-c — but it is an observational biomarker study, not a trial of administering MOTS-c as a treatment. *Consolidating review (2023).* A comprehensive review synthesized MOTS-c's discovery, its mitochondrial encoding, its AMPK/folate-cycle mechanism, its nuclear translocation, its inducibility by exercise, and its proposed roles across metabolic, stress-adaptive, and aging-related pathways — now the standard reference frame researchers cite when orienting new MOTS-c work [3]. *Exercise-mimetic effects in mice (2021).* Exercise was shown to induce endogenous MOTS-c expression in skeletal muscle and circulation in mice aged 2, 12, and 22 months. Exogenous MOTS-c significantly enhanced physical performance across all three age groups — including a significant increase in treadmill running capacity (P=0.000002), grip strength, and gait quality in aged mice — positioning MOTS-c as a candidate 'exercise-mimetic' for healthspan research [4]. *Nuclear retrograde signaling (2018).* In human and mouse cell models, MOTS-c was shown to translocate from mitochondria to the nucleus under metabolic stress, regulating nuclear gene expression in an AMPK-dependent manner — including antioxidant-response genes via the NRF2 pathway. This was the first demonstration of retrograde signaling by a mitochondrial-encoded peptide [5]. ## Reported effects, cautions & safety Chai Peptides has not found a body of curated, structured community-reported-effects data for MOTS-c the way it has for tirzepatide — consistent with a compound that has never been through a human interventional trial, let alone accumulated years of patient-community discussion. Rather than speculate, this section sticks to what the cited literature and regulatory record establish. *What the evidence does not yet cover.* Every finding above involves cells, mice, or rats — not a single published human trial has tested whether exogenous MOTS-c improves metabolism, performance, or an aging-related outcome in people [3]. There is no validated human pharmacokinetic profile: no measured human half-life, bioavailability, or dose-response relationship exists in the literature, and the rodent doses used in published work (0.5-15 mg/kg/day) do not translate to a human dose. *Regulatory and quality status.* MOTS-c is not approved by the FDA for any use and is sold only as a research chemical for laboratory use; because it is not regulated as a pharmaceutical, purity, identity, and sterility vary by supplier. Anti-doping authorities such as USADA and WADA treat MOTS-c as a prohibited peptide under hormone-and-metabolic-modulator categories, and athletes who use it face sanctions. *A genetic wrinkle.* Research has identified a pro-diabetogenic mitochondrial DNA variant (m.1382A>C) and ancestry-dependent differences in exercise response, suggesting MOTS-c's effects — whatever they ultimately prove to be in humans — are unlikely to be uniform across populations [3]. ## Where it fits in appetite, satiety, and metabolic-signaling research On this desk, MOTS-c represents the most fundamental — and least clinically proven — layer of metabolic signaling: energy sensing at the level of the mitochondrion itself, upstream of the hormone systems that [tesamorelin](/tesamorelin) and [tirzepatide](/tirzepatide) engage. Where tirzepatide works on gut-hormone receptors and appetite circuits, and tesamorelin works through the pituitary-liver-fat axis, MOTS-c's proposed mechanism — AMPK activation via CK2 and the folate cycle — sits closer to the cellular machinery that determines how a cell uses the fuel it has. It is the compound on this desk furthest from a clinic and closest to a laboratory bench. See how the three compare on the [comparison page](/compare). ![MOTS-c research illustration — abstract mitochondrial energy-flux motifs in dark forest green](/images/mots-c.webp) --- An independent, citation-first read of the metabolic and weight-research literature — enthusiasm always chased with a caveat, never with a diagnosis or a dose.